Suppr超能文献

α-葡萄糖苷酶抑制剂伏格列波糖的长期给药通过增加ob/ob小鼠中活性胰高血糖素样肽-1的分泌并降低二肽基肽酶-4的活性来提高其水平。

Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.

作者信息

Moritoh Yusuke, Takeuchi Koji, Hazama Masatoshi

机构信息

Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Yodogawa-ku, Osaka, Japan.

出版信息

J Pharmacol Exp Ther. 2009 May;329(2):669-76. doi: 10.1124/jpet.108.148056. Epub 2009 Feb 10.

Abstract

Administration of an alpha-glucosidase inhibitor, voglibose, increases the secretion of glucagon-like peptide (GLP)-1, a key modulator of pancreatic islet hormone secretion and glucose homeostasis. In the present study, novel mechanisms by which voglibose increases active GLP-1 circulation were evaluated. Voglibose (0.001 and 0.005%) was administered in the diet to ob/ob mice for 1 day or 3 to 4 weeks to determine effects on incretin profiles and plasma activity of dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for GLP-1 degradation. Voglibose showed no direct inhibitory effect against DPP-4 in vitro (DPP-4 inhibitor alogliptin, IC(50) < 10 nM). Likewise, 1-day treatment with voglibose did not change plasma DPP-4 activity; however, it increased plasma active GLP-1 by 1.6- to 3.4-fold. After chronic treatment, voglibose stimulated GLP-1 secretion, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. Plasma DPP-4 activity was decreased unexpectedly by 40 to 51%, resulting from reduced plasma DPP-4 concentrations in voglibose-treated mice. Voglibose increased GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively. The increased GLP-1 content in the colon was associated with elevated expression of gut glucagon gene. Chronic treatment with voglibose resulted in 1.9- to 4.1-fold increase in active GLP-1 circulation, which was higher than 1-day treatment. A similar treatment with pioglitazone (0.03%), an insulin sensitizer, did not affect plasma DPP-4 activity or GLP-1 levels. These results suggest that increased GLP-1 secretion, decreased DPP-4 activity, and increased gut GLP-1 content may have contributed to increased active GLP-1 circulation after chronic treatment with voglibose in a glucose control-independent manner in ob/ob mice.

摘要

给予α-葡萄糖苷酶抑制剂伏格列波糖可增加胰高血糖素样肽(GLP)-1的分泌,GLP-1是胰岛激素分泌和葡萄糖稳态的关键调节因子。在本研究中,评估了伏格列波糖增加活性GLP-1循环的新机制。将伏格列波糖(0.001%和0.005%)添加到饮食中给予ob/ob小鼠1天或3至4周,以确定其对肠促胰岛素谱和二肽基肽酶-4(DPP-4,一种负责GLP-1降解的酶)血浆活性的影响。伏格列波糖在体外对DPP-4没有直接抑制作用(DPP-4抑制剂阿格列汀,IC50<10 nM)。同样,伏格列波糖治疗1天也不会改变血浆DPP-4活性;然而,它可使血浆活性GLP-1增加1.6至3.4倍。长期治疗后,伏格列波糖刺激GLP-1分泌,血浆活性加非活性酰胺化GLP-1水平增加1.3至1.5倍证明了这一点。伏格列波糖治疗的小鼠血浆DPP-4浓度降低,导致血浆DPP-4活性意外降低40%至51%。伏格列波糖使下肠道和结肠中的GLP-1含量分别增加1.5至1.6倍和1.4至1.6倍。结肠中GLP-1含量的增加与肠道胰高血糖素基因表达升高有关。伏格列波糖长期治疗使活性GLP-1循环增加1.9至4.1倍,高于1天治疗。使用胰岛素增敏剂吡格列酮(0.03%)进行类似治疗不会影响血浆DPP-4活性或GLP-1水平。这些结果表明,在ob/ob小鼠中,长期使用伏格列波糖治疗后,GLP-1分泌增加、DPP-4活性降低以及肠道GLP-1含量增加可能以与葡萄糖控制无关的方式导致活性GLP-1循环增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验